TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026
Regeneron Pharmaceuticals, Inc. has announced a strategic collaboration with TriNetX to gain access to de-identified electronic health records (EHRs) from approximately 300 million patients, significantly enhancing its capabilities in drug discovery, clinical development, and digital health innovation. The partnership enables Regeneron to integrate large-scale genomic and proteomic datasets with real-world clinical data, creating one of the most comprehensive EHR-linked biomedical databases in the industry and reinforcing the growing role of artificial intelligence (AI) and real-world evidence (RWE) in modern pharmaceutical research.
Massive EHR Integration Accelerates Drug Discovery
Under the collaboration, Regeneron gains secure access to TriNetX’s global network of health data, covering approximately 300 million anonymized patient records, including 170 million individuals in the United States, sourced from thousands of healthcare providers worldwide. This large-scale dataset will be integrated with Regeneron Genetics Center (RGC) resources, which already include millions of sequenced exomes and proteomic profiles, enabling deep phenotypic and molecular analysis at unprecedented scale.
By combining clinical, genomic, and proteomic data, the company aims to identify novel disease targets, validate therapeutic pathways, and optimize clinical trial design, significantly improving the efficiency and success rates of drug development pipelines. The collaboration represents a major step toward data-driven precision medicine, where advanced analytics and AI models can uncover previously hidden biological insights.
Novel Prodrug Design Enhances Muscle Targeting
Advertisement
UX016 is a next-generation small molecule prodrug composed of sialic acid (SA) linked to a hydrophobic fatty acid tail, designed to improve tissue distribution and cellular uptake, particularly in skeletal muscle. This advanced formulation addresses key limitations of earlier substrate replacement therapies by enabling enhanced delivery and sustained release of sialic acid within muscle cells, thereby restoring normal glycoprotein and glycolipid function.
Preclinical studies have demonstrated that UX016 can increase sialic acid levels across multiple muscle groups and restore them toward near-normal levels, suggesting its potential to slow or modify disease progression. By targeting the underlying metabolic deficiency in sialic acid biosynthesis, UX016 represents a precision medicine approach aimed at correcting the root cause of GNE myopathy rather than merely managing symptoms.
AI and Real-World Data Transform Clinical Research
A key objective of the partnership is to leverage AI-powered algorithms trained on real-world health data to support both therapeutic innovation and digital health solutions. The integration of longitudinal patient records with molecular datasets allows researchers to better understand disease progression, treatment outcomes, and patient variability, enabling more targeted and personalized treatment strategies.
Importantly, all data usage will comply with global privacy regulations such as HIPAA and GDPR, ensuring secure and ethical handling of patient information. The collaboration also highlights the increasing importance of real-world evidence (RWE) in regulatory decision-making and clinical development, as pharmaceutical companies move beyond traditional trial models toward data-rich, AI-enhanced research ecosystems.
Strategic Investment and Future Digital Health Innovation
As part of the agreement, Regeneron will invest up to $200 million in TriNetX, underscoring the strategic importance of this partnership in advancing next-generation healthcare technologies. The expanded dataset is expected to support not only drug discovery and development, but also the creation of innovative digital health tools aimed at improving disease prediction, prevention, and management.
By leveraging machine learning, genomics, and real-world clinical data, Regeneron is positioning itself at the forefront of a data-centric transformation in life sciences, where integrated platforms drive faster innovation and improved patient outcomes. This collaboration reflects a broader industry shift toward converging biotechnology and digital health, enabling more efficient, scalable, and personalized approaches to medicine.
With this collaboration, Regeneron strengthens its leadership in data-driven drug development, harnessing the power of AI, genomics, and real-world data to accelerate the discovery of life-changing therapies while shaping the future of digital health and precision medicine.
Source: Regeneron, TriNetX press release
